Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Rheumatology

Predicting Your Path: The Five-Factor Score (FFS)

At a Glance

The EGPA Five-Factor Score (FFS) is a medical tool used to predict disease severity and guide treatment. An FFS of 0 indicates lower risk, typically treated with steroids, while a score of 1 or higher suggests organ-threatening disease requiring stronger immunosuppressants to protect your body.

When you are diagnosed with a systemic disease like EGPA, one of the first things your medical team will do is assess the “intensity” of your illness. To do this, doctors use a validated prognostic tool called the Five-Factor Score (FFS) [1][2]. This score helps your doctor decide whether your disease is “organ-threatening” and whether you need intensive treatments like chemotherapy-based immunosuppressants [1][3].

The 2009 FFS

The 2009 version is often preferred because it more accurately predicts outcomes in modern patients [4]. It assigns 1 point each for:

  • Age > 65 years
  • Cardiac involvement
  • Severe GI involvement
  • Kidney Involvement: Defined as Creatinine ≥ 1.7 mg/dL. (For context, a normal creatinine level is roughly 0.7 to 1.2 mg/dL. A level of 1.7 or higher means the kidneys are actively struggling to filter waste).
  • Lack of ENT symptoms (+1 point). This sounds counterintuitive, but patients who do have severe nasal polyps or sinus issues often have a more limited form of the disease that is less likely to damage internal organs [5].

Why These Factors Matter

  • Cardiac Involvement: This is a leading cause of severe complications in EGPA [6]. Inflammation of the heart muscle (myocarditis) or the lining of the heart (pericarditis) can lead to heart failure or dangerous heart rhythms [7][8].
  • GI Involvement: Severe abdominal pain or bleeding can indicate that the blood vessels in the bowel are inflamed, which may lead to serious complications like bowel perforation [9][10].
  • Renal (Kidney) Involvement: Kidneys filter blood, making them highly vulnerable to inflamed blood vessels [1].

How the Score Changes Your Treatment

  1. FFS = 0 (Low Risk): Your disease is considered non-severe. Treatment usually begins with high-dose glucocorticoids (steroids), often paired with medications like mepolizumab to help lower the steroid dose [3][11].
  2. FFS ≥ 1 (Higher Risk): This indicates “organ-threatening” or severe disease [1]. To protect your organs and induce remission quickly, your doctor will likely recommend combining steroids with a more powerful immunosuppressant, such as cyclophosphamide or rituximab [1][12].

Common questions in this guide

What is the Five-Factor Score (FFS) for EGPA?
The Five-Factor Score is a tool doctors use to measure the severity of EGPA. It helps determine if the disease is threatening major organs and guides which treatments are most appropriate for your specific situation.
What factors make up the 2009 FFS?
The score assigns one point each for being over age 65, having heart involvement, experiencing severe gastrointestinal issues, having kidney disease, and lacking ear, nose, and throat (ENT) symptoms.
Why does a lack of ENT symptoms increase my FFS score?
It may seem surprising, but patients who have severe nasal polyps or sinus issues often have a more limited form of EGPA. A lack of these ENT symptoms is actually associated with a higher risk of internal organ damage.
How does my FFS score change my treatment plan?
An FFS of 0 means a lower risk, often treated with steroids and mepolizumab. A score of 1 or higher indicates severe disease that usually requires stronger medications, like cyclophosphamide or rituximab, to quickly protect your organs.
What are the signs of heart or gastrointestinal involvement in EGPA?
Heart involvement may cause shortness of breath or ankle swelling. Gastrointestinal issues can cause severe abdominal pain, persistent nausea, or bloody stools. You should report any of these symptoms to your doctor immediately.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my Five-Factor Score (FFS) based on my current tests?
  2. 2.How does my score affect the decision to use more aggressive medications like cyclophosphamide versus starting with mepolizumab?
  3. 3.Since I have no chest pain, are we certain there is no 'silent' cardiac involvement that would change my FFS?
  4. 4.Does my lack of ENT symptoms mean we should be monitoring my kidney and heart health more closely?
  5. 5.How often will we reassess these factors to see if my risk level has changed?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss).

    Nguyen Y, Guillevin L

    Seminars in respiratory and critical care medicine 2018; (39(4)):471-481 doi:10.1055/s-0038-1669454.

    PMID: 30404114
  2. 2

    [Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)].

    Jerrentrup A, Müller T, Mariss J, Dylla S

    Der Internist 2018; (59(5)):497-504 doi:10.1007/s00108-017-0303-3.

    PMID: 28983650
  3. 3

    2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

    Chung SA, Langford CA, Maz M, et al.

    Arthritis care & research 2021; (73(8)):1088-1105 doi:10.1002/acr.24634.

    PMID: 34235880
  4. 4

    Comparison of the Birmingham Vasculitis Activity Score and the Five-Factor Score to Assess Survival in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Study of 550 Patients From Spain (REVAS Registry).

    Solans-Laqué R, Rodriguez-Carballeira M, Rios-Blanco JJ, et al.

    Arthritis care & research 2020; (72(7)):1001-1010 doi:10.1002/acr.23912.

    PMID: 31033198
  5. 5

    Long-Term Followup of a Multicenter Cohort of 101 Patients With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss).

    Durel CA, Berthiller J, Caboni S, et al.

    Arthritis care & research 2016; (68(3)):374-87 doi:10.1002/acr.22686.

    PMID: 26315340
  6. 6

    Severe heart failure and intracardiac thrombosis: going beyond the appearance for diagnosis and treatments.

    Segreti A, Mastroberardino S, Frau L, et al.

    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace 2025; (95(2)) doi:10.4081/monaldi.2024.2882.

    PMID: 38700128
  7. 7

    Cardiac manifestations of eosinophilic granulomatosis with polyangiitis from a single-center cohort in China: clinical features and associated factors.

    Liu S, Guo L, Zhang Z, et al.

    Therapeutic advances in chronic disease 2021; (12()):2040622320987051 doi:10.1177/2040622320987051.

    PMID: 33613936
  8. 8

    A rare case of eosinophilic granulomatosis with polyangiitis complicated with progressive pericardial effusion.

    Arinaga T, Komaki T, Miura SI, et al.

    Journal of cardiology cases 2017; (15(5)):163-166 doi:10.1016/j.jccase.2017.01.001.

    PMID: 30279769
  9. 9

    Similarities and differences of clinical manifestations and prognosis between eosinophilic gastroenteritis and eosinophilic granulomatosis with polyangiitis complicating gastrointestinal involvement.

    Li K, Jia Y, Ruan G, et al.

    Clinical rheumatology 2025; (44(3)):1259-1268 doi:10.1007/s10067-024-07286-8.

    PMID: 39821126
  10. 10

    Clinical characteristics and long-term outcome of patients with gastrointestinal involvement in eosinophilic granulomatosis with polyangiitis.

    Li R, Chen Y, Zhang S, et al.

    Frontiers in immunology 2022; (13()):1099722 doi:10.3389/fimmu.2022.1099722.

    PMID: 36713417
  11. 11

    Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.

    Wechsler ME, Akuthota P, Jayne D, et al.

    The New England journal of medicine 2017; (376(20)):1921-1932 doi:10.1056/NEJMoa1702079.

    PMID: 28514601
  12. 12

    Severe eosinophilic granulomatosis with polyangiitis responding to a combination of rituximab and mepolizumab.

    Tsioulos G, Kounatidis D, Vallianou NG, et al.

    The American journal of the medical sciences 2023; (365(1)):93-98 doi:10.1016/j.amjms.2022.07.007.

    PMID: 35970248

This page explains the EGPA Five-Factor Score (FFS) for educational purposes only and does not replace professional medical advice. Always consult your rheumatologist or healthcare team to discuss your specific score and treatment options.

Get notified when new evidence is published on Eosinophilic granulomatosis with polyangiitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.